Prognostic and predictive biomarkers in melanoma

被引:8
作者
Maher, Nigel G. [1 ,2 ,3 ,4 ]
Vergara, Ismael A. [1 ,4 ,5 ]
Long, Georgina V. [1 ,4 ,5 ,6 ]
Scolyer, Richard A. [1 ,2 ,3 ,4 ,5 ,7 ]
机构
[1] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[2] Royal Prince Alfred Hosp, Tissue Pathol & Diag Oncol, Sydney, NSW, Australia
[3] NSW Hlth Pathol, Sydney, NSW, Australia
[4] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia
[5] Univ Sydney, Charles Perkins Ctr, Sydney, NSW, Australia
[6] Royal North Shore & Mater Hosp, Sydney, NSW, Australia
[7] Royal Prince Alfred Hosp, Tissue Pathol & Diag Oncol, Bldg 94 via John Hopkins Dr,Missenden Rd, Camperdown, NSW 2050, Australia
基金
澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;
关键词
Melanoma; biomarkers; AMERICAN JOINT COMMITTEE; NODE-POSITIVE MELANOMA; STAGE IV MELANOMA; NEOADJUVANT IMMUNOTHERAPY; DESMOPLASTIC MELANOMA; PATHOLOGICAL RESPONSE; METASTATIC MELANOMA; CUTANEOUS MELANOMA; POOLED ANALYSIS; BRAF MUTATIONS;
D O I
10.1016/j.pathol.2023.11.004
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Biomarkers help to inform the clinical management of patients with melanoma. For patients with clinically localised primary melanoma, biomarkers can help to predict postsurgical outcome (including via the use of risk prediction tools), better select patients for sentinel lymph node biopsy, and tailor catch-all follow-up protocols to the individual. Systemic drug treatments, including immune checkpoint inhibitor (ICI) therapies and BRAF-targeted therapies, have radically improved the prognosis of metastatic (stage III and IV) cutaneous melanoma patients, and also shown benefit in the earlier setting of stage IIB/C primary melanoma. Unfortunately, a response is far from lished, and emerging, prognostic, and predictive pathological biomarkers that refine clinical decision-making in expression profile assays and nomograms are emerging astatic cutaneous melanoma, and the HLA-A*02:01 allele for the use of a bispecific fusion protein in metastatic uveal Australian clinical practice guidelines. Further research, validation, and assessment of clinical utility is required idly integrated into routine care.
引用
收藏
页码:259 / 273
页数:15
相关论文
共 179 条
  • [81] Gene Expression Profiling-Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome
    Jonsson, Goran
    Busch, Christian
    Knappskog, Stian
    Geisler, Jurgen
    Miletic, Hrvoje
    Ringner, Markus
    Lillehaug, Johan R.
    Borg, Ake
    Lonning, Per Eystein
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (13) : 3356 - 3367
  • [82] Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
    Joseph, Richard W.
    Elassaiss-Schaap, Jeroen
    Kefford, Richard
    Hwu, Wen-Jen
    Wolchok, Jedd D.
    Joshua, Anthony M.
    Ribas, Antoni
    Hodi, F. Stephen
    Hamid, Omid
    Robert, Caroline
    Daud, Adil
    Dronca, Roxana
    Hersey, Peter
    Weber, Jeffrey S.
    Patnaik, Amita
    de Alwis, Dinesh P.
    Perrone, Andrea
    Zhang, Jin
    Kang, S. Peter
    Ebbinghaus, Scot
    Anderson, Keaven M.
    Gangadhar, Tara C.
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (20) : 4960 - 4967
  • [83] Uveal melanoma: Estimating prognosis
    Kaliki, Swathi
    Shields, Carol L.
    Shields, Jerry A.
    [J]. INDIAN JOURNAL OF OPHTHALMOLOGY, 2015, 63 (02) : 93 - 102
  • [84] Evaluation of a Gene Expression Profiling Assay in Primary Cutaneous Melanoma
    Kangas-Dick, Aaron W.
    Greenbaum, Alissa
    Gall, Victor
    Groisberg, Roman
    Mehnert, Janice
    Chen, Chunxia
    Moore, Dirk F.
    Berger, Adam C.
    Koshenkov, Vadim
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (08) : 4582 - 4589
  • [85] Early Detection and Prognostic Assessment of Cutaneous Melanoma Consensus on Optimal Practice and the Role of Gene Expression Profile Testing
    Kashani-Sabet, Mohammed
    Leachman, Sancy A.
    Stein, Jennifer A.
    Arbiser, Jack L.
    Berry, Elizabeth G.
    Celebi, Julide T.
    Curiel-Lewandrowski, Clara
    Ferris, Laura K.
    Grant-Kels, Jane M.
    Grossman, Douglas
    Kulkarni, Rajan P.
    Marchetti, Michael A.
    Nelson, Kelly C.
    Polsky, David
    Seiverling, Elizabeth V.
    Swetter, Susan M.
    Tsao, Hensin
    Verdieck-Devlaeminck, Alexandra
    Wei, Maria L.
    Bar, Anna
    Bartlett, Edmund K.
    Bolognia, Jean L.
    Bowles, Tawnya L.
    Cha, Kelly B.
    Chu, Emily Y.
    Hartman, Rebecca I.
    Hawryluk, Elena B.
    Jampel, Risa M.
    Karapetyan, Lilit
    Kheterpal, Meenal
    Lawson, David H.
    Leming, Philip D.
    Liebman, Tracey N.
    Ming, Michael E.
    Sahni, Debjani
    Savory, Stephanie A.
    Shaikh, Saba S.
    Sober, Arthur J.
    Sondak, Vernon K.
    Spaccarelli, Natalie
    Usatine, Richard P.
    Venna, Suraj
    Kirkwood, John M.
    [J]. JAMA DERMATOLOGY, 2023, 159 (05) : 545 - 553
  • [86] Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis
    Kolla, Avani M.
    Vitiello, Gerardo A.
    Friedman, Erica B.
    Sun, James
    Potdar, Aishwarya
    Daou, Hala
    Farrow, Norma E.
    Farley, Clara R.
    Vetto, John T.
    Han, Dale
    Tariq, Marvi
    Beasley, Georgia M.
    Contreras, Carlo M.
    Lowe, Michael
    Zager, Jonathan S.
    Osman, Iman
    Berman, Russell S.
    Liebman, Tracey N.
    Stein, Jennifer A.
    Lee, Ann Y.
    [J]. CANCER CONTROL, 2021, 28
  • [87] Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis
    Kuk, Deborah
    Shoushtari, Alexander N.
    Barker, Christopher A.
    Panageas, Katherine S.
    Munhoz, Rodrigo R.
    Momtaz, Parisa
    Ariyan, Charlotte E.
    Brady, Mary Sue
    Coit, Daniel G.
    Bogatch, Kita
    Callahan, Margaret K.
    Wolchok, Jedd D.
    Carvajal, Richard D.
    Postow, Michael A.
    [J]. ONCOLOGIST, 2016, 21 (07) : 848 - 854
  • [88] Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma
    Ladstein, Rita G.
    Bachmann, Ingeborg M.
    Straume, Oddbjorn
    Akslen, Lars A.
    [J]. BMC CANCER, 2010, 10
  • [89] Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
    Larkin, J.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Grob, J-J
    Rutkowski, P.
    Lao, C. D.
    Cowey, C. L.
    Schadendorf, D.
    Wagstaff, J.
    Dummer, R.
    Ferrucci, P. F.
    Smylie, M.
    Hogg, D.
    Hill, A.
    Marquez-Rodas, I.
    Haanen, J.
    Guidoboni, M.
    Maio, M.
    Schoffski, P.
    Carlino, M. S.
    Lebbe, C.
    McArthur, G.
    Ascierto, P. A.
    Daniels, G. A.
    Long, G. V.
    Bastholt, L.
    Rizzo, J. I.
    Balogh, A.
    Moshyk, A.
    Hodi, F. S.
    Wolchok, J. D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (16) : 1535 - 1546
  • [90] Lee JW, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-14512-9, 10.1038/s41467-020-15726-7]